geovax labs, inc., (otcqb: govx) is a clinical-stage biotechnology company developing human vaccines against infectious diseases using our modified vaccinia ankara - virus-like particle (mva-vlp) vaccine platform. our development programs are focused on preventive vaccines against hiv, zika virus, hemorrhagic fever viruses (ebola, sudan, marburg, and lassa), and malaria, as well as therapeutic vaccines for chronic hepatitis b infections and cancers. our mva-vlp platform supports in vivo production of non-infectious vlps from the cells of the very person receiving the vaccine, mimicking a natural infection, and stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. for more information, visit www.geovax.com.
Company profile
Ticker
GOVX, GOVXW
Exchange
Website
CEO
David Dodd
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
DAUPHIN TECHNOLOGY INC
SEC CIK
Corporate docs
Subsidiaries
GeoVax, Inc. • Immutak Oncology, Inc. ...
IRS number
870455038
GOVX stock data
Latest filings (excl ownership)
DEF 14A
Definitive proxy
15 Apr 24
PRE 14A
Preliminary proxy
3 Apr 24
EFFECT
Notice of effectiveness
14 Mar 24
10-K/A
2023 FY
Annual report (amended)
11 Mar 24
EFFECT
Notice of effectiveness
11 Mar 24
EFFECT
Notice of effectiveness
11 Mar 24
EFFECT
Notice of effectiveness
11 Mar 24
EFFECT
Notice of effectiveness
11 Mar 24
8-K
GeoVax Reports 2023 Year-End Financial Results
1 Mar 24
S-3
Shelf registration
1 Mar 24
Transcripts
GOVX
Earnings call transcript
2023 Q3
8 Nov 23
GOVX
Earnings call transcript
2023 Q2
9 Aug 23
GOVX
Earnings call transcript
2023 Q1
4 May 23
GOVX
Earnings call transcript
2022 Q4
23 Mar 23
GOVX
Earnings call transcript
2022 Q3
10 Nov 22
GOVX
Earnings call transcript
2022 Q2
3 Aug 22
GOVX
Earnings call transcript
2022 Q1
28 Apr 22
GOVX
Earnings call transcript
2021 Q4
10 Mar 22
GOVX
Earnings call transcript
2021 Q3
12 Nov 21
GOVX
Earnings call transcript
2021 Q2
12 Aug 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 12.69 mm | 12.69 mm | 12.69 mm | 12.69 mm | 12.69 mm | 12.69 mm |
Cash burn (monthly) | 1.70 mm | 1.83 mm | 2.87 mm | 2.04 mm | 1.70 mm | 1.83 mm |
Cash used (since last report) | 11.32 mm | 12.20 mm | 19.08 mm | 13.55 mm | 11.30 mm | 12.18 mm |
Cash remaining | 1.37 mm | 491.64 k | -6.39 mm | -865.31 k | 1.38 mm | 508.28 k |
Runway (months of cash) | 0.8 | 0.3 | -2.2 | -0.4 | 0.8 | 0.3 |
Institutional ownership, Q2 2023
91.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 18 |
Opened positions | 2 |
Closed positions | 3 |
Increased positions | 2 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 866.53 mm |
Total shares | 1.98 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 730.99 k | $402.04 mm |
BLK Blackrock | 413.44 k | $227.39 mm |
Cavalry Fund I Management | 219.34 k | $1.01 mm |
Geode Capital Management | 172.75 k | $95.01 mm |
Bigger Capital Fund L P | 151.12 k | $511.00 k |
STT State Street | 97.94 k | $53.87 mm |
MS Morgan Stanley | 50.20 k | $27.61 mm |
Two Sigma Securities | 36.81 k | $20.24 mm |
NTRS Northern Trust | 34.21 k | $18.82 mm |
VIRT Virtu Financial | 27.10 k | $15.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Feb 24 | David A Dodd | Common Stock | Buy | Acquire P | No | No | 2.2735 | 8,209 | 18.66 k | 18,661 |
21 Feb 24 | David A Dodd | Common Stock | Buy | Acquire P | No | No | 2.15 | 520 | 1.12 k | 10,452 |
7 Feb 24 | Mark Reynolds | Common Stock | Buy | Acquire P | No | No | 2.77 | 2,000 | 5.54 k | 7,213 |
22 Dec 23 | Kelly T. Jr. McKee | Common Stock | Buy | Acquire P | No | No | 0.36 | 6,944 | 2.50 k | 35,782 |
25 Sep 23 | Kelly T. Jr. McKee | Common Stock | Buy | Acquire P | No | No | 0.52 | 9,653 | 5.02 k | 28,838 |
25 Aug 23 | David A Dodd | Common Stock | Buy | Acquire P | No | No | 0.57 | 35,087 | 20.00 k | 148,957 |
News
WHO's Tedros Adhanom Ghebreyesus Posts On X "In #DRC alone, more than 4500 cases of #mpox and almost 300 deaths have been reported this year. That is triple the number reported at this time last year. The recent surge in cases and deaths among children is of particular concern, along with the re-emergence of Clade One in central Africa...."
11 Apr 24
12 Health Care Stocks Moving In Friday's Pre-Market Session
5 Apr 24
GeoVax To Present Data On GEO-CM04S1, A Next Generation Covid-19 Vaccine, At The World Vaccine Congress
28 Mar 24
Earnings Scheduled For February 29, 2024
29 Feb 24
Earnings Outlook For Geovax Labs
28 Feb 24